Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD, Hanley PJ, Chi YY, Aguayo-Hiraldo P, Dvorak CC, Verneris MR, Kohn DB, Pai SY, Dávila Saldaña BJ, Hanisch B, Quigg TC, Adams RH, Dahlberg A, Chandrakasan S, Hasan H, Malvar J, Jensen-Wachspress MA, Lazarski CA, Sani G, Idso JM, Lang H, Chansky P, McCann CD, Tanna J, Abraham AA, Webb JL, Shibli A, Keating AK, Satwani P, Muranski P, Hall E, Eckrich MJ, Shereck E, Miller H, Mamcarz E, Agarwal R, De Oliveira SN, Vander Lugt MT, Ebens CL, Aquino VM, Bednarski JJ, Chu J, Parikh S, Whangbo J, Lionakis M, Zambidis ET, Gourdine E, Bollard CM, Pulsipher MA. Keller MD, et al. Among authors: lazarski ca. Nat Commun. 2024 Apr 18;15(1):3258. doi: 10.1038/s41467-024-47057-2. Nat Commun. 2024. PMID: 38637498 Free PMC article. Clinical Trial.
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication.
Keller MD, Schattgen SA, Chandrakasan S, Allen EK, Jensen-Wachspress MA, Lazarski CA, Qayed M, Lang H, Hanley PJ, Tanna J, Pai SY, Parikh S, Berger SI, Gottschalk S, Pulsipher MA, Thomas PG, Bollard CM. Keller MD, et al. Among authors: lazarski ca. Nat Commun. 2024 Mar 29;15(1):2749. doi: 10.1038/s41467-024-47056-3. Nat Commun. 2024. PMID: 38553461 Free PMC article.
Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency.
Miller HK, Hanley PJ, Lang H, Lazarski CA, Chorvinsky EA, McCormack S, Roesch L, Albihani S, Dean M, Hoq F, Adams RH, Bollard CM, Keller MD. Miller HK, et al. Among authors: lazarski ca. Biol Blood Marrow Transplant. 2018 Sep;24(9):1944-1946. doi: 10.1016/j.bbmt.2018.04.030. Epub 2018 May 9. Biol Blood Marrow Transplant. 2018. PMID: 29753156 Free PMC article.
T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.
Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM. Keller MD, et al. Among authors: lazarski ca. Br J Haematol. 2019 Oct;187(2):206-218. doi: 10.1111/bjh.16053. Epub 2019 Jun 20. Br J Haematol. 2019. PMID: 31219185 Free PMC article. Clinical Trial.
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products.
Durkee-Shock J, Lazarski CA, Jensen-Wachspress MA, Zhang A, Son A, Kankate VV, Field NE, Webber K, Lang H, Conway SR, Hanley PJ, Bollard CM, Keller MD, Schwartz DM. Durkee-Shock J, et al. Among authors: lazarski ca. Mol Ther Methods Clin Dev. 2022 Jun 9;25:439-447. doi: 10.1016/j.omtm.2022.04.013. Epub 2022 Apr 29. Mol Ther Methods Clin Dev. 2022. PMID: 35506060 Free PMC article.
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, Keswani A, Webber KC, Montgomery-Recht K, Walkiewicz M, Notarangelo LD, Burbelo PD, Fuss I, Cohen JI, Bollard CM, Keller MD. Kinoshita H, et al. Among authors: lazarski ca. J Clin Immunol. 2021 Aug;41(6):1146-1153. doi: 10.1007/s10875-021-01046-y. Epub 2021 May 13. J Clin Immunol. 2021. PMID: 33983545 Free PMC article.
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein.
Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, Durkee-Shock J, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson EM, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem U, Stanojevic M, Geiger A, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CR, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM. Keller MD, et al. Among authors: lazarski ca. Blood. 2020 Dec 17;136(25):2905-2917. doi: 10.1182/blood.2020008488. Blood. 2020. PMID: 33331927 Free PMC article.
37 results